Nicotinic Acid Restriction Potentiates NAMPT Inhibition in Acute Myeloid Leukemia Xenograft Models
5 affiliations
- 1Division of Cancer Chemotherapy, Miyagi Cancer Center Research Institute, Natori, Japan.
- 2Department of Biochemical Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan.
- 3Department of Respiratory Medicine, Miyagi Cancer Center Hospital, Natori, Japan.
- 4Multi Omics Platform, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
- 5Human Biology-Microbiome-Quantum Research Center, Keio University, Tokyo, Japan.
Abstract
Nicotinamide phosphoribosyltransferase (NAMPT), a key enzyme in NAD biosynthesis, is a potential therapeutic target in cancer. Acute myeloid leukemia (AML) is among cancer types exhibiting high NAMPT dependence, and elevated NAMPT activity is implicated in venetoclax resistance. Thus, pharmacologic NAMPT inhibitors (NAMPTi) have been developed as a promising therapeutic approach in some cancers. However, our current knowledge of in vivo factors that determine NAMPTi therapeutic efficacy is incomplete. In this study, using mouse models we found that NAMPTi efficacy against AML is limited by dietary nicotinic acid (NA). Specifically, NA and NA riboside (NAR), an NA-derived metabolite, promoted NAD biosynthesis independent of NAMPT and rescued AML cells from NAMPTi-mediated toxicity in vitro. Importantly, in AML xenograft models, dietary NA restriction, which selectively reduces circulating NAR levels, enhanced antitumor efficacy of NAMPTis and prolonged animal survival. Although the combination treatment caused transient hematologic toxicity, peripheral blood cell counts largely recovered after treatment. Our findings highlight systemic NAD precursor metabolism, including NAR, as a determinant of responses to NAMPT-targeted therapies. We conclude that NA restriction may improve the therapeutic efficacy of NAMPTis in AML.
Significance:: NAMPT is a potential therapeutic target in AML, but factors governing treatment response remain undefined. Building on findings that dietary NA maintains circulating NAR levels, we demonstrate that this pathway provides a critical escape mechanism from NAMPT inhibition. We show that NA restriction sensitizes AML to NAMPTis, significantly improving survival in vivo, identifying systemic NAD precursor metabolism as a key determinant of therapeutic efficacy.
Related
- Citronellol Potentiates Antibiotics Against Escherichia coli O157:H7 via Inhibition of Biofilm Formation
- The Endogenous Negative Allosteric Modulator, Lynx1, Inhibits Nicotinic Cholinergic Signaling in the Ventral Tegmental Area to Regulate Nicotine Reinforcement
- XenoMix: estimating mouse content from DNA methylation data of Patient-Derived Xenograft models
- The mode of action of neonicotinoids and related compounds on insect neuronal nicotinic acetylcholine receptors highlights complex intracellular calcium mechanisms
- Mass photometry and its expanding role in membrane protein research: The Torpedo marmorata nicotinic acetylcholine receptor as case study
BibTeX
@article{tsurumi2026nicotinic,
title = {{Nicotinic Acid Restriction Potentiates NAMPT Inhibition in Acute Myeloid Leukemia Xenograft Models}},
author = {Kyoji Tsurumi and Miyuki Nomura and Mai Ohuchi and Ryoma Kizu and Naohiko Kikuchi and Taku Sato and Mami Morita and Yoji Yamashita and Kayoko Hayashi and Tomoyoshi Soga and Yuki Sugiura and Tatsuro Fukuhara and Nobuhiro Tanuma},
journal = {Cancer Research Communications},
year = {2026},
month = oct,
doi = {10.1158/2767-9764.crc-26-0274},
url = {https://doi.org/10.1158/2767-9764.crc-26-0274},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Nicotinic Acid Restriction Potentiates NAMPT Inhibition in Acute Myeloid Leukemia Xenograft Models
AU - Kyoji Tsurumi
AU - Miyuki Nomura
AU - Mai Ohuchi
AU - Ryoma Kizu
AU - Naohiko Kikuchi
AU - Taku Sato
AU - Mami Morita
AU - Yoji Yamashita
AU - Kayoko Hayashi
AU - Tomoyoshi Soga
AU - Yuki Sugiura
AU - Tatsuro Fukuhara
AU - Nobuhiro Tanuma
PY - 2026
DA - 2026/10/28
JO - Cancer Research Communications
DO - 10.1158/2767-9764.crc-26-0274
UR - https://doi.org/10.1158/2767-9764.crc-26-0274
AB - Nicotinamide phosphoribosyltransferase (NAMPT), a key enzyme in NAD biosynthesis, is a potential therapeutic target in cancer. Acute myeloid leukemia (AML) is among cancer types exhibiting high NAMPT dependence, and elevated NAMPT activity is implicated in venetoclax resistance. Thus, pharmacologic NAMPT inhibitors (NAMPTi) have been developed as a promising therapeutic approach in some cancers. However, our current knowledge of in vivo factors that determine NAMPTi therapeutic efficacy is incomplete. In this study, using mouse models we found that NAMPTi efficacy against AML is limited by dietary nicotinic acid (NA). Specifically, NA and NA riboside (NAR), an NA-derived metabolite, promoted NAD biosynthesis independent of NAMPT and rescued AML cells from NAMPTi-mediated toxicity in vitro. Importantly, in AML xenograft models, dietary NA restriction, which selectively reduces circulating NAR levels, enhanced antitumor efficacy of NAMPTis and prolonged animal survival. Although the combination treatment caused transient hematologic toxicity, peripheral blood cell counts largely recovered after treatment. Our findings highlight systemic NAD precursor metabolism, including NAR, as a determinant of responses to NAMPT-targeted therapies. We conclude that NA restriction may improve the therapeutic efficacy of NAMPTis in AML. Significance:: NAMPT is a potential therapeutic target in AML, but factors governing treatment response remain undefined. Building on findings that dietary NA maintains circulating NAR levels, we demonstrate that this pathway provides a critical escape mechanism from NAMPT inhibition. We show that NA restriction sensitizes AML to NAMPTis, significantly improving survival in vivo, identifying systemic NAD precursor metabolism as a key determinant of therapeutic efficacy.
SN - 2767-9764
ER -